Moderna, Inc. Share Price

Equities

MRNA

US60770K1079

Biotechnology & Medical Research

Market Closed - Nasdaq 21:00:00 14/06/2024 BST 5-day change 1st Jan Change
140 USD -3.58% Intraday chart for Moderna, Inc. -7.27% +40.80%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site
Sales 2024 * 4.17B 328B Sales 2025 * 4.84B 382B Capitalization 53.67B 4,230B
Net income 2024 * -2.68B -211B Net income 2025 * -2.02B -159B EV / Sales 2024 * 11.4 x
Net cash position 2024 * 6.25B 493B Net cash position 2025 * 3.94B 311B EV / Sales 2025 * 10.3 x
P/E ratio 2024 *
-19.8 x
P/E ratio 2025 *
-26.7 x
Employees 5,600
Yield 2024 *
-
Yield 2025 *
-
Free-Float 90.43%
More Fundamentals * Assessed data
Dynamic Chart
1 day-3.58%
1 week-7.27%
Current month-1.77%
1 month+8.50%
3 months+34.84%
6 months+62.81%
Current year+40.80%
More quotes
1 week
138.17
Extreme 138.17
152.28
1 month
129.67
Extreme 129.67
170.47
Current year
84.06
Extreme 84.06
170.47
1 year
62.55
Extreme 62.55
170.47
3 years
62.55
Extreme 62.55
497.49
5 years
11.54
Extreme 11.54
497.49
10 years
11.54
Extreme 11.54
497.49
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 28/02/11
Director of Finance/CFO 47 05/09/22
President 48 31/12/12
Members of the board TitleAgeSince
Director/Board Member 65 31/05/18
Director/Board Member 74 30/06/20
Director/Board Member 67 10/12/19
More insiders
Date Price Change Volume
14/06/24 140 -3.58% 3,601,293
13/06/24 145.2 -1.69% 1,815,199
12/06/24 147.7 -0.45% 3,486,003
11/06/24 148.4 -0.13% 1,924,981
10/06/24 148.6 -1.60% 5,969,563

Delayed Quote Nasdaq, June 14, 2024 at 09:00 pm

More quotes
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows: - revenue from product sales (95.7%) ; - revenues from grants (4%); - revenues from collaboration agreements (0.3%). At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development. Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
140 USD
Average target price
145.2 USD
Spread / Average Target
+3.67%
Consensus
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW